Last reviewed · How we verify
MR4
MR4 is an investigational compound in development by Astellas Pharma, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | MR4 |
|---|---|
| Also known as | Modified Release Tacrolimus, FK506MR, FK506E |
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published mechanisms, the precise molecular target and pharmacological action of MR4 cannot be reliably determined. Astellas has not released comprehensive mechanistic information for this Phase 3 candidate in the public domain.
Approved indications
Common side effects
Key clinical trials
- Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® (PHASE2)
- Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (PHASE3)
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (PHASE2)
- Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (PHASE2)
- Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (PHASE2)
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML (PHASE2)
- Development and Validation of Interpretable Machine Learning Models Incorporating Paraspinal Muscle Quality for to Predict Cage Subsidence Risk Followingposterior Lumbar Interbody Fusion
- Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MR4 CI brief — competitive landscape report
- MR4 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI